Table S9. Balance in baseline covariates of all tofacitinib-treated and tocilizumab-treated RA patients in the cohort, grouped by the status of previous bDMARD use, after IPTW adjustment

	bDMARD-naïve patients (n = 274)		Previous bDMARD-experienced patients (n = 329)	
	Tofacitinib versus tocilizumab		Tofacitinib versus tocilizumab	
	ASD*		ASD*	
	Before IPTW	After IPTW	Before IPTW	After IPTW
Age	0.13	0.050	0.31	0.005
Male sex	0.18	0.040	0.012	0.025
RA duration	0.14	0.020	0.28	0.012
Advanced stages	0.040	0.050	0.17	0.011
Anti-CCP-positive	0.050	0.010	0.040	0.001
RF-positive	0.13	0.010	0.002	0.006
CDAI	0.090	0.030	0.047	0.034
Previous MTX failure	0.58	0.030	0.047	0.049
Previous bDMARD failure	−	−	0.041	0.005
Concurrent MTX use	0.30	0.030	0.17	0.004
Concurrent PSL use	0.46	0.030	0.40	0.017

*Balance in each of the baseline covariates was checked between the tofacitinib and tocilizumab groups before and after IPTW adjustment, separately in bDMARD-naïve patients and bDMARD-failure patients. ASD of <0.10 indicates that the baseline covariates were well balanced between the two treatment groups.

RA, rheumatoid arthritis; bDMARD, biological disease-modifying antirheumatic drug; anti-CCP, anti-cyclic citrullinated peptide antibodies; RF, rheumatoid factor; MTX, methotrexate; PSL, prednisolone; CDAI, clinical disease activity index; IPTW, inverse probability of treatment weighting; ASD, absolute standardized difference